One proposed strategy to suppress the proliferation of imatinib-resistant cells in chronic myeloid leukemia (CML) is to inhibit key proteins downstream of Bcr-Abl. The PI3K/Akt pathway is activated by Bcr-Abl and is specifically required for the growth of CML cells. To identify targets of this pathway, we undertook a proteomic screen and identified several proteins that differentially bind 14-3-3, dependent on Bcr-Abl kinase activity. An siRNA screen of candidates selected by bioinformatics analysis reveals coldshock domain protein A (CSDA), shown previously to regulate cell cycle progression in epithelial cells, to be a positive regulator of proliferation in a CML cell line. We show that Akt can phosphorylate the serine 134 residue of CSDA but, downstream of Bcr-Abl activity, this modification is mediated through the activation of MEK/p90 ribosomal S6 kinase (RSK) signaling. Chronic myeloid leukemia (CML) is a stem cell disease, in which neoplastic cells carry a translocated Philadelphia chromosome, in which a hybrid Bcr-ABL gene encodes a fusion oncoprotein, Bcr-Abl, with constitutive tyrosine kinase activity. Bcr-Abl induces multiple signaling pathways to transduce the oncogenic signal, which ultimately results in uncontrolled proliferation and neoplastic expansion.
One proposed strategy to suppress the proliferation of IM-resistant cells is to inhibit key proteins downstream of BcrAbl, such as Akt. Previous reports have shown that 14-3-3-affinity purification can be used to identify novel Akt substrates in cells in which Akt is activated through exposure to epidermal growth factor. 8 Owing to the fact that the PI3K/ Akt pathway plays a crucial role in the leukemogenesis of CML 9,10 and 14-3-3 binds to a number of well-characterized Akt targets in cancer signaling, 11, 12 we postulated that such 14-3-3 binding would significantly contribute to Bcr-Ablmediated leukemogenesis. We therefore utilized 14-3-3 affinity binding methodology to identify proteins that are regulated by Akt downstream of Bcr-Abl. Here we report that cold-shock domain protein A (CSDA) is a target of Bcr-Ablinduced phosphorylation, regulates proliferation and is critical for Bcr-Abl-induced transformation.
Results
Identification and comparative analysis of IM-sensitive 14-3-3 binding proteins in Bcr-Abl-positive CML cells. To identify Bcr-Abl-dependent 14-3-3 binding proteins, GST-14-3-3-affinity purification was utilized in combination with mass spectrometry to identify sufficient numbers of 14-3-3 bound proteins to detect differential binding after inhibition of Bcr-Abl kinase activity. The affinity purification was undertaken in whole-cell lysates from LAMA84 CML cells cultured in the presence or absence of IM as described in Materials and Methods (Figure 1a) . Phosphotyrosine western blots of lysate inputs for the affinity purification displays a significant reduction in the level of tyrosine phosphorylation of multiple proteins after treatment with IM, confirming efficacy of the inhibitor in our assay (Figure 1b) . Furthermore, enrichment of tyrosinephosphorylated proteins was detected among the untreated 14-3-3 binding proteins in the pulldown (Figure 1b) .
In total, 318 proteins were identified by mass spectrometry as being bound to 14-3-3 (Supplementary Table 1 ). In order to assess the robustness of the GST-14-3-3-affinity purification technique, we performed bioinformatic analysis of published interactions (www.hrpd.org) and confirmed that a number of proteins that bound to 14-3-3 in our affinity purification screen had previously been shown to bind 14-3-3 (Supplementary Table 2 ). The previous identification of these proteins as 14-3-3 binding proteins was achieved through a variety of techniques, including GST-affinity purification, Tandemaffinity purification and immunoprecipitation. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] This reassured us that the eluates from the GST-14-3-3-affinity purifications were highly enriched for 14-3-3 binding proteins and that the proteins we identified were not artifactual results generated by the use of the GST-14-3-3-affinity purification technique.
Of the 318 proteins, 69 bound 14-3-3 only in the absence of IM treatment. We focused on these proteins since we were interested only in putative Akt targets that were regulated by Bcr-Abl activity in CML. In accord with other 14-3-3-affinity purification screens and the critical role of PI3K/Akt signaling in cancer cell biology, 15, 17, 23 grouping of these proteins by biological function, as described by the Human Protein Figure 1 Identification and analysis of Bcr-Abl-dependent 14-3-3-interacting proteins. (a) Schema of GST-14-3-3-affinity purification from IM-sensitive CML cells. Lysates from LAMA84 cells untreated or treated with 5 mM for 2 h were incubated with GST-14-3-3-sepharose; bound proteins were eluted and identified by mass spectrometry as described in Materials and Methods. (b) Aliquots of eluates from affinity purification were analyzed by Coomassie staining and western blot with phospho-tyrosine antibody. (c) Proteins that bound 14-3-3 only in the absence of IM were grouped by biological functions as described in the text Reference Database (www.hrpd.org), enriched for protein metabolism (33%), nucleic acid metabolism (20%), signal transduction (17%), as well as energy and metabolism (16%) (Supplementary Table 3 , Figure 1c ).
siRNA screen for proliferation of candidate Bcr-Abldependent Akt targets. On the basis of phosphorylationsite motif analysis for 14-3-3 binding and Akt kinase motifs (http://scansite.mit.edu), as well as functional analysis, 20 of the 69 proteins that bound to 14-3-3 only in cells with active Bcr-Abl were selected for inclusion in a customized siRNA screen for proliferation (Supplementary Table 4 ). Two siRNA sequences were used for any gene that had pre-validated siRNAs, whereas three siRNA sequences were used for genes for which two pre-validated siRNAs were not available (Supplementary Table 5 ). The K562 cell line was used for the siRNA screen because of their relatively high transfection efficiency as well as their wide use in studying CML. Cells were transfected with the siRNA oligonucleotides and proliferation assessed by MTS 48 h post transfection as described in Materials and Methods. Proliferation was normalized to a non-targeting siRNA control and a 'cell death' siRNA was included as a positive control for siRNAmediated decrease of proliferation ( Figure 2a) .
As shown in Figure 2a , transfection of three of the 20 candidates included in the screen resulted in 420% decrease of proliferation: 5-aminoimidazol-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC, Entrez Gene ID 471), glucose phosphate isomerase (GPI, Entrez Gene ID 2821) and CSDA (Entrez Gene ID 8531). The latter has been shown to be a transcription factor, shuttling between tight junctions and nuclei, promoting cell proliferation. 24, 25 We selected CSDA (also called ZONAB) for further analysis as besides enhancing cell proliferation, it has recently been implicated in breast cancer metastasis and shown to be upregulated in gastric cancer. 26, 27 Its role in CML or other CSDA is phosphorylated in a Bcr-Abl-dependent manner in CML cells and CML patient samples. Examining the CSDA amino-acid sequence, we noted striking similarity with the recently identified Akt site on YB-1, 28 a closely related cold-shock domain containing protein. We generated a phospho-deficient serine to alanine construct (CSDAS134A) targeting the putative Akt site and expressed it along with wild-type CSDA in 293 cells. Western blot analysis with a phospho-specific commercial antibody (pYB1) to the homologous site on YB-1 (serine 102) determined that this reagent could be used to detect specific phosphorylation on serine S134 of CSDA ( Figure 3a) .
We next developed FLAG-CSDA-expressing stable LAMA84 and K562 cell lines to assess Bcr-Abl-dependent phosphorylation of CSDA in CML. As shown in Figure 3b , immunoprecipitation of FLAG-CSDA followed by immunoblotting with pYB-1 of lysates from both stable cell lines treated with IM results in profound decrease in S134 phosphorylation of CSDA, revealing Bcr-Abl-dependent phosphorylation.
To determine whether Bcr-Abl-dependent CSDA phosphorylation is detectable in actual CML, we purified CD34 þ cells from leukaphareses from CML patients or normal donors as described in Materials and methods. Western blot analysis ( Figure 3c ) revealed that lysates derived from CML cells (sample ID 37 and 44) show Bcr-Abl expression and a concomitant increase in phosphorylation of CrkL, a substrate for Bcr-Abl and a widely used readout for Bcr-Abl activity 29, 30 relative to lysates from healthy individuals (sample ID 35 and 43). Tellingly, CML cells also exhibited increased phosphorylated CSDA signal relative to CSDA expression as compared with normal cells, indicating greater specific phosphorylation of CSDA at serine 134 in Bcr-Abl-positive CML.
Bcr-Abl-induced CSDA phosphorylation is independent of Akt, but dependent on MEK/RSK pathway. Bcr-Abl activates a number of downstream signaling pathways besides PI3K/Akt. To investigate whether Bcr-Abl-induced CSDA phosphorylation is dependent on Akt activity, we co-expressed CSDA with either empty vector or Bcr-Abl in 293 cells, and treated them with control vehicle or a specific Akt inhibitor (Akti VIII). Western blot analysis revealed that Akt inhibition is effective in decreasing the basal CSDA phosphorylation in vector control cells, but not in Bcr-Abltransfected cells (Figure 4a ).
In order to determine which kinases are responsible for Bcr-Abl-induced CSDA phosphorylation, we co-transfected 293 cells with CSDA and empty vector or Bcr-Abl, and treated them with control vehicle, mTOR inhibitor (rapamycin), PI3K inhibitor (LY294002), active MEK inhibitor (U0126), MEK inhibitor (PD98059) or p38 MAPK inhibitor (SB203580). As shown in the top panel of Figure 4b , treatment with the PI3K inhibitor but not the other inhibitors reduced basal CSDA phosphorylation. Similar to our findings with Akt (Figure 4a Sequence analysis led us to expect that MEK does not directly phosphorylate CSDA at serine 134. However, the p90 ribosomal S6 kinase (RSK) was recently reported to phosphorylate the conserved site on YB-1 and RSK signaling downstream of MEK activity is well established. 31, 32 Tellingly, treatment with an RSK inhibitor (SL0101) blocked Bcr-Ablinduced CSDA phosphorylation as effectively as MEK inhibition (Figure 4c ). These data suggest that although Akt phosphorylates CSDA at serine 134 in non-CML cells, Bcr-Abl activity results in MEK-dependent RSK phosphorylation of CSDA at the same site. RSK inhibition specifically blocks proliferation in Bcr-Abl-positive cell lines and primary CML cells. We investigated whether RSK activity is selectively critical in Bcr-Abl-positive cells by undertaking a proliferation assay comparing K562 and Ramos cell lines. As expected, treatment with IM selectively blocked proliferation in K562 CML cells while having negligible effect on the Bcr-Ablnegative, Ramos Burkitt's lymphoma line, whereas Akt inhibition decreased proliferation in both cell lines (Figure 5a) . Strikingly, similar to IM, RSK inhibition reduced proliferation only in the K562 cells (Figure 5a ). We assessed whether the difference in sensitivity to RSK inhibitor may be a function of differential S6 kinase activity in these cells. Indeed, although Ramos and K562 cells express similar levels of both RSK1 and RSK2, the K562 CML lines exhibit markedly increased S6 kinase activity as detected by an antibody specific to S6 kinase phosphorylated at Thr389 (Figure 5b) .
To determine whether specificity to RSK inhibition is also evidenced in primary CML cells, we compared the proliferation rate of normal and CML CD34 þ progenitors treated with IM, Akt inhibitor or RSK inhibitor. Similar to what we observed in the cell lines (Figure 5a ), IM-induced Bcr-Abl inhibition and RSK inhibition affected growth only of CML progenitor cells, whereas Akt inhibition abrogated proliferation in both CML and normal cells (Figure 5c ). These data indicate that inhibition of RSK specifically reduces proliferation in Bcr-Abl-positive cells, both in cell lines and primary CML.
CSDA expression and S134 phosphorylation regulates Bcr-Abl-dependent transformation. We have shown that CSDA expression and RSK activity are both critical for proliferation in CML (Figures 2b and 5) . We have also discovered that CSDA is phosphorylated at serine 134 downstream of Bcr-Abl in an RSK-dependent manner (Figure 4 ). To determine whether CSDA S134 phosphorylation is critical for Bcr-Abl-dependent transformation, we generated stable lines expressing empty vector or coexpressing Bcr-Abl and empty vector, CSDA or the CSDAS134A phospho-deficient mutant in Rat1 cells to employ in soft agar colony formation assays. 33, 34 After selection, we validated the expression of Bcr-Abl and CSDA constructs (Figure 6a) . Furthermore, using phosphospecific antibodies to CrkL and CSDA, we confirmed that expressed Bcr-Abl was active, and that expressed CSDA, but not CSDAS134A protein, exhibits increased phosphorylation at serine 134A with Bcr-Abl co-expression ( Figure 6a ). As shown in Figure 6b , cells stably expressing Bcr-Abl generated significantly greater number of colonies when cultured in soft agar than cells only expressing empty vector. Colony formation was further and significantly enhanced from cells co-expressing Bcr-Abl and CSDA, but not the phosphodeficient CSDAS134A construct compared with Bcr-Abl and empty vector (Figure 6b ). In fact, co-expression of Bcr-Abl and CSDAS134A resulted in lower number of colonies than BcrAbl alone. These findings reveal that CSDA phosphorylation as well as expression is critical for Bcr-Abl-mediated malignant transformation.
Discussion
We showed that CSDA is specifically phosphorylated at serine 134 downstream of Bcr-Abl in CML cell lines and primary progenitor cells from CML patients (Figure 3) . However, we unexpectedly determined that CSDAS134 phosphorylation is dependent on Akt in the absence of (a) Rat1 fibroblasts were stably co-transfected with relevant empty vectors (EV) or pCDNA3.1Bcr-Abl and empty vector or pBabe_flagCSDA or pBabe_flagCSDA as indicated, and lysates analyzed by western blot for the expression of Bcr-Abl, phosphorylated CrkL, phosphorylated CSDA, CSDA and tubulin as described previously. (b) Indicated Rat1 stable cell lines were cultured in soft agar and analyzed for colony formation as described in Materials and methods. Three independent experiments were each carried out in triplicate and data presented are mean value ± SD of one representative experiment. EV versus EV þ Bcr-Abl: ***t ¼ 10.75, P ¼ 0.0017; Bcr-Abl þ EV versus Bcr-Abl þ CSDA: **t ¼ 6.971, P ¼ 0.02; Bcr-Abl þ EV versus Bcr-Abl þ CSDAS134A: ***t ¼ 11.9, P ¼ 0.0003. Representative pictures are provided Bcr-Abl, but dependent on MEK/RSK downstream of Bcr-Abl (Figure 4) . RSK targets such as S6 are key regulators of translation and S6 phosphorylation downstream of MEK activity was shown to be via RSK rather than mTOR to stimulate cap-dependant translation. 35, 36 Although CSDA has been reported to function as a transcription factor, activating target genes such as PCNA and cyclin D1 that regulate proliferation and morphogenesis in epithelial cells, 24, 37 we did not detect significant changes in specific luciferase activity of either PCNA-or cyclin D1-luciferase constructs, co-expressed with Bcr-Abl and either CSDA or CSDAS134A constructs (data not shown).
It may be that Bcr-Abl-MEK-RSK signaling induces CSDA to regulate translation rather than transcription to promote proliferation in CML. Interestingly, the closely related coldshock domain-containing protein, YB-1, has been shown to regulate translation in breast cancer progression by repressing cap-dependent and promoting cap-independent mechanisms, with Akt phosphorylation at serine 102 resulting in decreased cap-complex binding of YB-1, and thus decreased translational repression in breast and other epithelial cells. 28, [38] [39] [40] It will be interesting to determine if there are similar cap-dependent and -independent differences in RSK versus Akt phosphorylation of CSDA at serine 134 (homologous to serine 102 in YB-1) in regulating translation in CML-and Bcr-Abl-negative leukemias, and if blocking CSDAS134 phosphorylation can be exploited to specifically target CML.
We also showed that inhibition of RSK activity specifically blocks proliferation, similarly to CSDA silencing, in an established Bcr-Abl-positive cell line as well as in primary progenitor cells from CML patients ( Figure 5 ). Furthermore, we showed that CSDA, but not the RSK phospho-site mutant, enhances Bcr-Abl-dependent transformation. In fact, co-expression of CSDAS134A blocks Bcr-Abl-dependent transformation. However, it is probable that other RSK phosphorylation targets, both known and undiscovered, are also critical for tumorigenesis, and future work will determine if particular substrates are relevant for specific cancers. Unsurprisingly, proteins involved in protein synthesis, processing and fate were enriched in our bioinformatics analysis of 14-3-3 binding proteins in our initial proteomic screen for BcrAbl effectors in CML (Figure 1c) .
In this study, we selected CSDA for further investigation based on its previous known function in regulating cell cycle progression and upregulated expression in epithelial cancers, 24, 26, 27 as well as its scoring highly in a secondary targeted siRNA screen for proliferation in K562 CML cells (Figures 2a) . Gene ontology analysis of the Bcr-Abl-dependent 14-3-3 binders revealed enrichment for proteins involved in energy and metabolism (Supplementary Table 3 , Figure 1c ). Interestingly, the other two proteins that scored highly in the siRNA proliferation screen, ATIC, which catalyzes the last two steps of de novo purine biosynthesis, and GPI, which catalyzes the reversible isomerization of glucose-6-phosphate and fructose-6-phosphate, are both key metabolic enzymes linked to hematological malignancies 41, 42 ( Figure 2a) . Therefore, metabolic regulation downstream of Bcr-Abl can also be targeted in CML, as it has been in therapy for other cancers. 43, 44 The findings in this study indicate that CSDA phosphorylation and RSK signaling in general may offer an alternative to PI3K/Akt inhibition in targeting Bcr-Abldependent leukemogenesis.
Materials and Methods
Cell culture, transfection and treatment. LAMA84, K562 and Ramos cell lines were cultured in suspension in RPMI 1640 medium (Invitrogen, Paisley, UK), supplemented with 10% heat-inactivated fetal calf serum (Harlan Sera-Lab Ltd, Loughborough, UK), 5000 IU/ml penicillin, 5000 mm/ml streptomycin and 200 mM L-glutamine. The 293T and Rat1 cell lines were cultured in Dulbecco's modified Eagle's media (Invitrogen) supplemented as above.
Transfections of cDNA in 293T and Rat1 cells were performed with Effectene (Qiagen, Crawley, UK) according to the manufacturer's instructions. Rat1 stable cell lines were generated with co-selection in G418 and puromycin (Invitrogen). Retroviral infections of LAMA84 and K562 were performed as described previously, 45 and stable cell lines were generated with selection in puromycin. siRNA transfection in K562 and Ramos cells were performed with Interferin (Polyplus, Illkirch, France) according to the manufacturer's instructions.
IM was kindly provided by Dr. E Buchdunger (Novartis Pharma, Basel, Switzerland). Akt inhibtor VIII, LY294002, rapamycin, U0126, PD98059 and SB203580 were all purchased from Calbiochem (Nottingham, UK). Cells were treated with inhibitors at the concentrations detailed in the figure legends. þ cells were labeled using MiniMACS technology according to the manufacturer's instructions (Miltenyi Biotec, Bisley, UK). Cells were resuspended in 350 ml of MACS buffer (phosphate-buffered saline (Gibco, Paisley, UK), 0.5% bovine serum albumin (PAA Laboratories, Pasching, AT) and 2 mM EDTA (Sigma, Gillingham, UK) per 10 8 cells with 100 ml FcR blocking reagent and 50 ml of microbeads conjugated to monoclonal anti-CD34 antibody (QBEND10) and incubated for 15 min at 41C. The cells were then washed and resuspended in 2 ml of MACS buffer per 10 8 cells. Labeled cells were then passed through a pre-washed MiniMACS column mounted on a magnet. Following this, the column was washed four times with MACS buffer, removed from the magnet and the cells eluted with 2 ml MACS buffer. The purity of the CD34 þ fraction was consistently above 96% as determined by flow cytometry (FACScalibur, Becton Dickinson, Oxford, UK) with anti-CD34 staining. Aliquots were immediately frozen for subsequent lysis for western blot analysis or cultured in leukemic cell growth media for proliferation assays.
Plasmids. pGEX6P1/14-3-3t was generated by subcloning the open-reading frame of human 14-3-3t into pGEX6P1 (Amersham Biosciences, Little Chalfont, UK). pCLAmpho and pcDNA3.1Bcr-Abl were described previously. 46, 47 pCMV2B_CSDA was generated by subcloning the open-reading frame of human CSDA (Origene, Rockville, MD, USA) into pCMV_Tag2B (Stratagene, La Jolla, CA, USA). pBabe_flagCSDA was cloned by PCR-mediated addition of a 5 0 BamHI restriction site and FLAG tag sequence (DYKDDDDK) and 3 0 EcoRI restriction site. The CDS with 5 0 FLAG tag was then ligated with BamHI-and EcoRI-digested pBabe. Construction of all vectors was confirmed by both restriction digestion and DNA sequencing CSDAS134A point mutant was constructed by site-directed mutagenesis kit (QuickChange XL, Stratagene) according to the manufacturer's instruction using the following primer synthesized by SigmaGenosys (Gillingham, UK): 5 0 -ACGGAAATATCTGCGCGCTGTAGGA GATGGAGAAA-3 0 . Point mutation was confirmed by DNA sequencing.
Western blotting and immunoprecipitation. Cells were lysed in icecold buffer containing 1% (v/v) Triton X-100, 0.05% (v/v) SDS,10 mM NaH 2 PO 4 , 150 mM NaCl, 5 mM EDTA, 10 mM NaF, 1 mM NaVO 3 , 5 nM molybdic acid, 100 nM okadaic acid, 1 mM DTT, 1 Â Protease Inhibitor Cocktail (PIC) (Roche, Burgess Hill, UK), 1 Â PhosSTOP phosphatase inhibitor cocktail (Roche) and resolved by SDS-PAGE transferred to PVDF membrane (Hybond-P, GE Healthcare, Little Chalfont, UK). Anti-phosphotyrosine antibody (4G10) was a kind gift from Professor B Druker (Oregon Health & Science University, Portland, OR, USA) and anti-CSDA (ZONAB) antibody was a kind gift from Professor Karl Matter (UCL, London, UK).
